Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia
We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2005-07, Vol.29 (7), p.849-853 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 853 |
|---|---|
| container_issue | 7 |
| container_start_page | 849 |
| container_title | Leukemia research |
| container_volume | 29 |
| creator | Scholl, Sebastian Loncarevic, Ivan F. Krause, Claudia Kunert, Christa Clement, Joachim H. Höffken, Klaus |
| description | We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation). |
| doi_str_mv | 10.1016/j.leukres.2004.12.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67887721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212605000184</els_id><sourcerecordid>67887721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-fa00d794d0677b4a3d061f60200c67ac3cf3d6fa55e3cc21d0f4a305bd459e343</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EoqXwCCBPbAnHcRwnE0JAoVIRS5ktxz4RLrmUOEHq2-OqkRhZ7H_4zu0j5JpBzIBld9u4xvGrRx8nAGnMkhiAnZA5yyWPRM7FKZkDS0WUsCSbkQvvtwAgClackxkTRcJkCnPy-eZa1-iahk7OjiFY51F7pGV4LO1autODw3agfofGVc7QZT3waLV5orq1NIQNbcYhQF3rqWupNuOAtNlj3TlLD1ti4_QlOat07fFq-hfkY_m8eXyN1u8vq8eHdWR4xoeo0gBWFqmFTMoy1TwEVmUQjjSZ1Iabitus0kIgNyZhFqoAgShtKgrkKV-Q22PfXd99j-gH1ThvsK51i93oVSbzXMqEBVAcQdN33vdYqV0fTPR7xUAdFKutmhSrg2LFEhUUh7qbacBYNmj_qianAbg_AhjO_HHYK2-CQIPW9WgGZTv3z4hf3XqP7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67887721</pqid></control><display><type>article</type><title>Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Scholl, Sebastian ; Loncarevic, Ivan F. ; Krause, Claudia ; Kunert, Christa ; Clement, Joachim H. ; Höffken, Klaus</creator><creatorcontrib>Scholl, Sebastian ; Loncarevic, Ivan F. ; Krause, Claudia ; Kunert, Christa ; Clement, Joachim H. ; Höffken, Klaus</creatorcontrib><description>We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation).</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2004.12.001</identifier><identifier>PMID: 15921740</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; AML ; Bone Marrow - pathology ; Female ; Flt3-ITD ; fms-Like Tyrosine Kinase 3 ; Gene Duplication ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute - genetics ; Male ; Middle Aged ; MRD ; Mutation ; Neoplasm, Residual - genetics ; Proto-Oncogene Proteins - genetics ; Receptor Protein-Tyrosine Kinases - genetics ; Recurrence ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Leukemia research, 2005-07, Vol.29 (7), p.849-853</ispartof><rights>2005 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-fa00d794d0677b4a3d061f60200c67ac3cf3d6fa55e3cc21d0f4a305bd459e343</citedby><cites>FETCH-LOGICAL-c363t-fa00d794d0677b4a3d061f60200c67ac3cf3d6fa55e3cc21d0f4a305bd459e343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2004.12.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15921740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scholl, Sebastian</creatorcontrib><creatorcontrib>Loncarevic, Ivan F.</creatorcontrib><creatorcontrib>Krause, Claudia</creatorcontrib><creatorcontrib>Kunert, Christa</creatorcontrib><creatorcontrib>Clement, Joachim H.</creatorcontrib><creatorcontrib>Höffken, Klaus</creatorcontrib><title>Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation).</description><subject>Adult</subject><subject>AML</subject><subject>Bone Marrow - pathology</subject><subject>Female</subject><subject>Flt3-ITD</subject><subject>fms-Like Tyrosine Kinase 3</subject><subject>Gene Duplication</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>MRD</subject><subject>Mutation</subject><subject>Neoplasm, Residual - genetics</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Receptor Protein-Tyrosine Kinases - genetics</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi0EoqXwCCBPbAnHcRwnE0JAoVIRS5ktxz4RLrmUOEHq2-OqkRhZ7H_4zu0j5JpBzIBld9u4xvGrRx8nAGnMkhiAnZA5yyWPRM7FKZkDS0WUsCSbkQvvtwAgClackxkTRcJkCnPy-eZa1-iahk7OjiFY51F7pGV4LO1autODw3agfofGVc7QZT3waLV5orq1NIQNbcYhQF3rqWupNuOAtNlj3TlLD1ti4_QlOat07fFq-hfkY_m8eXyN1u8vq8eHdWR4xoeo0gBWFqmFTMoy1TwEVmUQjjSZ1Iabitus0kIgNyZhFqoAgShtKgrkKV-Q22PfXd99j-gH1ThvsK51i93oVSbzXMqEBVAcQdN33vdYqV0fTPR7xUAdFKutmhSrg2LFEhUUh7qbacBYNmj_qianAbg_AhjO_HHYK2-CQIPW9WgGZTv3z4hf3XqP7w</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Scholl, Sebastian</creator><creator>Loncarevic, Ivan F.</creator><creator>Krause, Claudia</creator><creator>Kunert, Christa</creator><creator>Clement, Joachim H.</creator><creator>Höffken, Klaus</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia</title><author>Scholl, Sebastian ; Loncarevic, Ivan F. ; Krause, Claudia ; Kunert, Christa ; Clement, Joachim H. ; Höffken, Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-fa00d794d0677b4a3d061f60200c67ac3cf3d6fa55e3cc21d0f4a305bd459e343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>AML</topic><topic>Bone Marrow - pathology</topic><topic>Female</topic><topic>Flt3-ITD</topic><topic>fms-Like Tyrosine Kinase 3</topic><topic>Gene Duplication</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>MRD</topic><topic>Mutation</topic><topic>Neoplasm, Residual - genetics</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Receptor Protein-Tyrosine Kinases - genetics</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scholl, Sebastian</creatorcontrib><creatorcontrib>Loncarevic, Ivan F.</creatorcontrib><creatorcontrib>Krause, Claudia</creatorcontrib><creatorcontrib>Kunert, Christa</creatorcontrib><creatorcontrib>Clement, Joachim H.</creatorcontrib><creatorcontrib>Höffken, Klaus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scholl, Sebastian</au><au>Loncarevic, Ivan F.</au><au>Krause, Claudia</au><au>Kunert, Christa</au><au>Clement, Joachim H.</au><au>Höffken, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>29</volume><issue>7</issue><spage>849</spage><epage>853</epage><pages>849-853</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15921740</pmid><doi>10.1016/j.leukres.2004.12.001</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2005-07, Vol.29 (7), p.849-853 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67887721 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult AML Bone Marrow - pathology Female Flt3-ITD fms-Like Tyrosine Kinase 3 Gene Duplication Humans Karyotyping Leukemia, Myeloid, Acute - genetics Male Middle Aged MRD Mutation Neoplasm, Residual - genetics Proto-Oncogene Proteins - genetics Receptor Protein-Tyrosine Kinases - genetics Recurrence Retrospective Studies Treatment Outcome |
| title | Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A54%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Minimal%20residual%20disease%20based%20on%20patient%20specific%20Flt3-ITD%20and%20-ITT%20mutations%20in%20acute%20myeloid%20leukemia&rft.jtitle=Leukemia%20research&rft.au=Scholl,%20Sebastian&rft.date=2005-07-01&rft.volume=29&rft.issue=7&rft.spage=849&rft.epage=853&rft.pages=849-853&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2004.12.001&rft_dat=%3Cproquest_cross%3E67887721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67887721&rft_id=info:pmid/15921740&rft_els_id=S0145212605000184&rfr_iscdi=true |